Evidence map›Paper›PMID 26345723›Full record

ArticleDrug design, development and therapy2015

Development of megestrol acetate solid dispersion nanoparticles for enhanced oral delivery by using a supercritical antisolvent process.

Eun-Sol Ha, Jeong-Soo Kim, In-Hwan Baek, Jin-Wook Yoo, Yunjin Jung, Hyung Ryong Moon, Min-Soo Kim

Open access · goldAbstract read
In one paragraph

Article in Drug design, development and therapy, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
1.4field-weighted citation impact, top 23% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 35 citations in OpenAlex.

  1. Review
  2. Review
  3. Review
  4. Review
  5. Article
  6. PureAntioxidants (Basel, Switzerland) · 2020
    Article
  7. Article
  8. Review
  9. Review
  10. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 1 institution in 1 country.

Eun-Sol HaCollege of Pharmacy, Pusan National University, Yongin, South Korea.
Jeong-Soo KimDong-A ST Co Ltd, Yongin, South Korea.
In-Hwan BaekCollege of Pharmacy, Kyungsung University, Busan, South Korea.
Jin-Wook YooCollege of Pharmacy, Pusan National University, Yongin, South Korea.
Yunjin JungCollege of Pharmacy, Pusan National University, Yongin, South Korea.
Hyung Ryong MoonCollege of Pharmacy, Pusan National University, Yongin, South Korea.
Min-Soo KimCollege of Pharmacy, Pusan National University, Yongin, South Korea.
Kyungsung University · KR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

In the present study, solid dispersion nanoparticles with a hydrophilic polymer and surfactant were developed using the supercritical antisolvent (SAS) process to improve the dissolution and oral absorption of megestrol acetate. The physicochemical properties of the megestrol acetate solid dispersion nanoparticles were characterized using scanning electron microscopy, differential scanning calorimetry, powder X-ray diffraction, and a particle-size analyzer. The dissolution and oral bioavailability of the nanoparticles were also evaluated in rats. The mean particle size of all solid dispersion nanoparticles that were prepared was <500 nm. Powder X-ray diffraction and differential scanning calorimetry measurements showed that megestrol acetate was present in an amorphous or molecular dispersion state within the solid dispersion nanoparticles. Hydroxypropylmethyl cellulose (HPMC) solid dispersion nanoparticles significantly increased the maximum dissolution when compared with polyvinylpyrrolidone K30 solid dispersion nanoparticles. The extent and rate of dissolution of megestrol acetate increased after the addition of a surfactant into the HPMC solid dispersion nanoparticles. The most effective surfactant was Ryoto sugar ester L1695, followed by D-α-tocopheryl polyethylene glycol 1000 succinate. In this study, the solid dispersion nanoparticles with a drug:HPMC:Ryoto sugar ester L1695 ratio of 1:2:1 showed >95% rapid dissolution within 30 minutes, in addition to good oral bioavailability, with approximately 4.0- and 5.5-fold higher area under the curve (0-24 hours) and maximum concentration, respectively, than raw megestrol acetate powder. These results suggest that the preparation of megestrol acetate solid dispersion nanoparticles using the supercritical antisolvent process is a promising approach to improve the dissolution and absorption properties of megestrol acetate.

Indexed as

Chromatography, Supercritical FluidNanoparticlesAdministration, OralAnimalsArea Under CurveBiological AvailabilityCalorimetry, Differential ScanningChemistry, PharmaceuticalCrystallography, X-RayHypromellose DerivativesIntestinal AbsorptionMaleMegestrol AcetateMicroscopy, Electron, ScanningNanotechnologyPolyethylene GlycolsHypromellose DerivativesMegestrol AcetatePolyethylene GlycolsPovidoneProgesterone CongenersSurface-Active AgentstocophersolanVitamin Ebioavailabilitydissolutionmegestrol acetatesupercritical technology

Identifiers

PMID26345723
PMCPMC4531043
OpenAlexW1673088109

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.